Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

Journal of Immunology

Volumn 186, Issue 3, 2011, Pages 1840-1848

  De Weers, Michel ^a   Tai, Yu Tzu ^b   Van Der Veer, Michael S ^c   Bakker, Joost M ^a   Vink, Tom ^a   Jacobs, Daniëlle C H ^a   Oomen, Lukas A ^a   Peipp, Matthias ^d   Valerius, Thomas ^d   Slootstra, Jerry W ^e   Mutis, Tuna ^c   Bleeker, Wim K ^a   Anderson, Kenneth C ^b   Lokhorst, Henk M ^c   Van De Winkel, Jan G J ^a,c   Parren, Paul W H I ^a  

^a GENMAB   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF KIEL   (Germany)

^e Pepscan Systems   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; DARATUMUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOMA; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STROMA CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; BINDING SITES, ANTIBODY; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEK293 CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; NIH 3T3 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79251570884     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003032     Document Type: Article

References (51)

1. Raab, M. S., K. Podar, I. Breitkreutz, P. G. Richardson, and K. C. Anderson. 2009. Multiple myeloma. Lancet 374: 324-339.
2. Podar, K., Y. T. Tai, T. Hideshima, S. Vallet, P. G. Richardson, and K. C. Anderson. 2009. Emerging therapies for multiple myeloma. Expert Opin. Emerg. Drugs 14: 99-127.
3. Barlogie, B., F. van Rhee, J. D. Shaughnessy, Jr., E. Anaissie, and J. Crowley. 2008. Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia 22: 1633-1636.
4. Coiffier, B. 2003. Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma. Curr. Hematol. Rep. 2: 23-29.
5. Maloney, D. G. 2003. Rituximab for follicular lymphoma. Curr. Hematol. Rep. 2: 13-22.
6. Moreau, P., L. Voillat, L. Benboukher, C. Mathiot, C. Dumontet, N. Robillard, O. Hérault, F. Garnache, R. Garand, N. Varoqueaux, et al; IFM group. 2007. Rituximab in CD20 positive multiple myeloma. Leukemia 21: 835-836.
7. Zojer, N., K. Kirchbacher, M. Vesely, W. Hübl, and H. Ludwig. 2006. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk. Lymphoma 47: 1103-1109. (Pubitemid 44102973)
8. Treon, S. P., L. M. Pilarski, A. R. Belch, A. Kelliher, F. I. Preffer, Y. Shima, C. S. Mitsiades, N. S. Mitsiades, A. J. Szczepek, L. Ellman, et al. 2002. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J. Immunother. 25: 72-81.
9. Parren, P. W., and J. G. van de Winkel. 2008. An integrated science-based approach to drug development. Curr. Opin. Immunol. 20: 426-430.
10. Mehta, K., and F. Malavasi, eds. 2000. Human CD38 and Related Molecules. Karger, Basel, Switzerland.
11. Kawano, M. M., N. Huang, H. Harada, Y. Harada, A. Sakai, H. Tanaka, K. Iwato, and A. Kuramoto. 1993. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 82: 564-570.
12. Lin, P., R. Owens, G. Tricot, and C. S. Wilson. 2004. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 121: 482-488.
13. Malavasi, F., A. Funaro, S. Roggero, A. Horenstein, L. Calosso, and K. Mehta. 1994. Human CD38: a glycoprotein in search of a function. Immunol. Today 15: 95-97. (Pubitemid 24076322)
14. Deaglio, S., K. Mehta, and F. Malavasi. 2001. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res. 25: 1-12.
15. Stevenson, F. K., A. J. Bell, R. Cusack, T. J. Hamblin, C. J. Slade, M. B. Spellerberg, and G. T. Stevenson. 1991. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 77: 1071-1079.
16. Ellis, J. H., K. A. Barber, A. Tutt, C. Hale, A. P. Lewis, M. J. Glennie, G. T. Stevenson, and J. S. Crowe. 1995. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol. 155: 925-937.
17. Goldmacher, V. S., L. A. Bourret, B. A. Levine, R. A. Rasmussen, M. Pourshadi, J. M. Lambert, and K. C. Anderson. 1994. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 84: 3017-3025.
18. + hematological malignancies. Available at: http:// clinicaltrialsfeeds.org/clinical-trials/show/NCT01084252. Accessed: October 27, 2010.
19. Bleeker, W. K., M. E. Munk, W. J. Mackus, J. H. van den Brakel, M. Pluyter, M. J. Glennie, J. G. van de Winkel, and P. W. Parren. 2008. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 140: 303-312.
20. Rozemuller, H., E. van der Spek, L. H. Bogers-Boer, M. C. Zwart, V. Verweij, M. Emmelot, R. W. Groen, R. Spaapen, A. C. Bloem, H. M. Lokhorst, et al. 2008. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica 93: 1049-1057.
21. Kuipers, J., J. W. Vaandrager, D. O. Weghuis, P. L. Pearson, J. Scheres, H. M. Lokhorst, H. Clevers, and B. J. Bast. 1999. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet. Cytogenet. 109: 99-107.
22. Tai, Y. T., K. Podar, L. Catley, Y. H. Tseng, M. Akiyama, R. Shringarpure, R. Burger, T. Hideshima, D. Chauhan, N. Mitsiades, et al. 2003. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res. 63: 5850-5858.
23. Tai, Y. T., M. Dillon, W. Song, M. Leiba, X. F. Li, P. Burger, A. I. Lee, K. Podar, T. Hideshima, A. G. Rice, et al. 2008. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112: 1329-1337.
24. Burger, R., A. Guenther, F. Bakker, M. Schmalzing, S. Bernand, W. Baum, B. Duerr, G. M. Hocke, H. Steininger, E. Gebhart, and M. Gramatzki. 2001. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokineregulated tumor model for plasmacytoma. Hematol. J. 2: 42-53.
25. Lammerts van Bueren, J. J., W. K. Bleeker, H. O. Bøgh, M. Houtkamp, J. Schuurman, J. G. van de Winkel, and P. W. Parren. 2006. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 66: 7630-7638.
26. Bleeker, W. K., J. J. Lammerts van Bueren, H. H. van Ojik, A. F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M. A. van Dijk, et al. 2004. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 173: 4699-4707.
27. Teeling, J. L., R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. Parren, C. E. Hack, M. Dechant, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
28. Teeling, J. L., W. J. Mackus, L. J. Wiegman, J. H. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177: 362-371.
29. Weijer, K., C. H. Uittenbogaart, A. Voordouw, F. Couwenberg, J. Seppen, B. Blom, F. A. Vyth-Dreese, and H. Spits. 2002. Intrathymic and extrathymic development of human plasmacytoid dendritic cell precursors in vivo. Blood 99: 2752-2759.
30. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6: 443-446.
31. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758. (Pubitemid 34525533)
32. Fishwild, D. M., S. L. O'Donnell, T. Bengoechea, D. V. Hudson, F. Harding, S. L. Bernhard, D. Jones, R. M. Kay, K. M. Higgins, S. R. Schramm, and N. Lonberg. 1996. High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14: 845-851.
33. Lonberg, N., L. D. Taylor, F. A. Harding, M. Trounstine, K. M. Higgins, S. R. Schramm, C. C. Kuo, R. Mashayekh, K. Wymore, J. G. McCabe, et al. 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368: 856-859.
34. Zent, C. S., C. R. Secreto, B. R. LaPlant, N. D. Bone, T. G. Call, T. D. Shanafelt, D. F. Jelinek, R. C. Tschumper, and N. E. Kay. 2008. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res. 32: 1849-1856.
35. Cragg, M. S., and M. J. Glennie. 2004. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103: 2738-2743.
36. Kennedy, A. D., P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172: 3280-3288.
37. Beum, P. V., M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. Parren, J. G. van de Winkel, and R. P. Taylor. 2008. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 181: 822-832.
38. Pawluczkowycz, A. W., F. J. Beurskens, P. V. Beum, M. A. Lindorfer, J. G. van de Winkel, P. W. Parren, and R. P. Taylor. 2009. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183: 749-758.
39. Kraut, E. H., and A. L. Sagone, Jr. 1981. Alternative pathway of complement in multiple myeloma. Am. J. Hematol. 11: 335-345.
40. Zurlo, J. J., G. P. Schechter, and L. F. Fries. 1989. Complement abnormalities in multiple myeloma. Am. J. Med. 87: 411-420.
41. Cheson, B. D., R. R. Plass, and G. Rothstein. 1980. Defective opsonization in multiple myeloma. Blood 55: 602-606.
42. Weng, W. K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21: 3940-3947.
43. Zhang, W., M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima, M. Azuma, H. M. Chang, E. Borucka, G. Lurje, A. E. Sherrod, et al. 2007. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25: 3712-3718.
44. Uchida, A., M. Yagita, H. Sugiyama, T. Hoshino, and M. Moore. 1984. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int. J. Cancer 34: 375-381. (Pubitemid 14032188)
45. Benson, D. M., Jr., C. E. Bakan, A. Mishra, C. C. Hofmeister, Y. Efebera, B. Becknell, R. A. Baiocchi, J. Zhang, J. Yu, M. K. Smith, et al. 2010. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116: 2286-2294.
46. Tai, Y. T., X. F. Li, L. Catley, R. Coffey, I. Breitkreutz, J. Bae, W. Song, K. Podar, T. Hideshima, D. Chauhan, et al. 2005. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 65: 11712-11720.
47. van der Veer, M.S., M. de Weers, B. van Kessel, J. M. Bakker, S. Wittebol, P. W. H. I. Parren, H. M. Lokhorst, and T. Mutis. 2010. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by com- bination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica DOI:10.3324/haematol.2010.030759.
48. Funaro, A., A. L. Horenstein, L. Calosso, M. Morra, R. P. Tarocco, L. Franco, A. De Flora, and F. Malavasi. 1996. Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. Int. Immunol. 8: 1643-1650.
49. Hagenbeek, A., O. Gadeberg, P. Johnson, L. M. Pedersen, J. Walewski, A. Hellmann, B. K. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, et al. 2008. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111: 5486-5495.
50. McLaughlin, P., A. J. Grillo-López, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833.
51. Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD: visual molecular dynamics. J. Mol. Graph. 14: 33-38.